REVA Medical, Inc., a leader in bioresorbable polymer technologies for vascular applications, sponsored a symposium on May 23, 2018, at the Paris Course on Revascularization (“EuroPCR”) entitled FANTOM: the new vision of BRS performance, which highlighted 24-month data from the Company’s FANTOM II clinical trial.
Dr. Gregg Stone from the Columbia University Medical Center and the Cardiovascular Research Foundation and Dr. Ulf Landmesser from Charite Berlin chaired the symposium.
Dr. Alexandre Abizaid, Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, provided a review of the 24-month data from the FANTOM II trial, which included a low 5.0% rate of Major Adverse Cardiac Events (“MACE”) which demonstrates a strong safety profile for Fantom. Dr. Abizaid also discussed the Company’s expansion trials in long lesions, multi-vessel disease and acute myocardial infarction
Dr. Gregor Leibundgut from Kantonsspital Baselland in Liestal, Switzerland provided a review of Tyrocore, REVA’s proprietary polymer, which is different from the polylactic acid polymers used to construct first generation scaffolds such as Absorb. Tyrocore is the foundation for both Fantom, REVA’s current commercial product and Fantom Encore, the Company’s third generation product. The use of Tyrocore allows Fantom and Fantom Encore to offer improved features including a thinner strut profile, improved ease-of-use, and full x-ray visibility. Dr. Leibundgut also announced that Fantom Encore will have 95, 105 and 115 micron strut profiles for the 2.5, 3.0 and 3.5 mm diameters, respectively. The sequentially larger strut profiles for the three sizes are designed to achieve the thinnest strut profile possible while optimizing strength for each scaffold diameter. The 95 micron strut profile on the 2.5 mm diameter is the smallest strut profile of any commercially available BRS.
Dr. Neils Holm from the Skejby-Aarhus University Hospital in Aarhus, Denmark provided a review of the 24- month Optical Coherence Tomography (“OCT”) sub-study results. The OCT imaging results in a subset of patients treated with Fantom demonstrated vessel patency (maintenance of a wide open artery) and sustained healing with 100% strut coverage at 24 months.
Dr. Matthias Lutz from Universitatsklinikum Schleswig-Holstein in Kiel, Germany presented a selection of patient case reviews as well as an introduction to the Company’s implant technique, referred to as the REVA Technique.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.